Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Syndesis

Explore full profile

Market leader in the creation and activation of converged services for the new public network

New York City, United StatesFounded 2019Marketing
Valuation $100–250M Last recorded · 2000
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Syndesis and the history behind them.

About Syndesis

Syndesis operates as a unified global healthcare research platform, focusing on accelerating research, generating evidence, and complementing clinical trials. The company partners with hospitals, healthcare systems, and insurers outside of the United States to curate millions of de-identified patient journeys with deep longitudinality. Syndesis is also exploring the integration of clinical data with genomic sequencing to unlock additional insights. The platform enables joint analysis and comparison of data sets, co-identification of promising research areas, and the development of globally based research teams, grant applications, and shared research initiatives. By facilitating partnerships between network members, from hospitals to research organizations, Syndesis directly connects data providers with data users. The company serves a diverse range of clients, including healthcare providers, researchers, and insurers, operating primarily in the healthcare, life sciences, and biotech markets. Syndesis generates revenue through subscription fees for access to its platform and data sets, as well as through collaborative research projects and partnerships.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2019
Headquarters
New York City, United States
Employees
19
Open positions
None listed
Dealroom signal
75.9/100
Industry
Marketing
Sector
Marketing, Market Intelligence
Client focus
b2b

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Jan 2000 $33M $132M Sequoia —
SERIES AEquity / VC Jan 1999 — — Clear Ventures —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Syndesis website traffic

Latest recorded traffic for Syndesis is 6.3K monthly website visits, up 530% over the last three months. Syndesis's team grew 46.2% over the past year.

Latest monthly visits6.3K 3-month web change+530% 1-year team growth+46.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Clear Ventures

Series B and later1 investor entered at this stage

Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States40%
🇬🇧 United Kingdom30%
🇨🇴 Colombia20%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Syndesis on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Syndesis’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.